Company Overview of X-Chem, Inc.
X-Chem, Inc. operates as a subsidiary of Pharmaceutical Product Development Inc.
100 Beaver Street Suite 101
Waltham, MA 02453
Key Executives for X-Chem, Inc.
X-Chem, Inc. does not have any Key Executives recorded.
X-Chem, Inc. Key Developments
X-Chem, Inc. Enters into Licensing Agreement with Navitor Pharmaceuticals, Inc
Apr 1 15
X-Chem, Inc. has entered into a licensing agreement with Navitor Pharmaceuticals, Inc. for an exclusive license to a series of small molecules targeting the activation of mTORC1, a protein complex that orchestrates nutrient-mediated cellular metabolism and growth. The compounds licensed by Navitor were discovered by X-Chem screening their proprietary DEX platform against protein targets supplied by Navitor under a drug discovery agreement established by the parties in 2014. X-Chem has received research funding from Navitor upon initiation of the agreement and a license fee upon exercise of the license.
X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG
Dec 17 14
X-Chem, Inc. announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012. The latest program comprises several series of small molecule compounds against a cardiovascular drug target. Under the terms of this agreement, X-Chem will receive an upfront license fee in addition to payments based on the achievement of defined pre-clinical, clinical and sales milestones, as well as royalties. This license further validates the innovative nature of X-Chem’s team and approach.
X-Chem Signs Drug Discovery Collaboration with Alexion
Dec 15 14
X-Chem has signed drug discovery collaboration with Alexion. The contract has been signed for new therapies to treat patients with severe and ultra-rare disorders. According to the agreement, X-Chem will deploy its drug discovery engine, which is based on an ultra-large, high-diversity library in excess of 100 billion molecules, to identify new drug candidates against targets chosen by Alexion. The contract will see X-Chem receive an upfront payment and receive additional payments upon the achievement of specified research, development and regulatory milestones. X-Chem will also receive royalty payments on the sale of products resulting from the collaboration.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2014
Most Searched Private Companies
Sponsored Financial Commentaries